Outcome of direct-acting antiviral treatment for patients with chronic hepatitis C virus infection: clinical benefit proven?

Raoel Maan, Adriaan J. van der Meer


The highly effective direct-acting antivirals (DAAs) for the treatment of chronic hepatitis C virus (HCV) infection were well-received by both patients and physicians as sustained virological response (SVR) was associated with an improved overall survival in patients with stable liver disease, even in case of cirrhosis (1). Yet, at that time these results were derived from retrospective cohort studies with long-term follow-up after interferon-based therapy.